The Food and Drug Administration has authorized the sale of a second Antibiotice drug on the US market, namely Nafcilina (nafcillin) injection, the company said.
Antibiotice already exports ampicillin to the American market and estimates it will receive approval to sell two other products over the next two years.
The company reported net profit of 23.1 million lei ($7.35 million) in the first half, up 34% on the year, while total sales increased 20% to RON138.5 million. The increase in sales was mainly due to rising exports, Antibiotice said.
Antibiotice is the second-largest nystatin maker in the world, with a 25% market share, according to company information.
The company’s majority holder is Romania’s Health Ministry, with a 53% stake, while investment fund SIF Oltenia (SIF5.RO) holds a 10% stake.
At around 12:00 local time Monday, Antibiotice traded up 0.24% at RON0.42 a share in Bucharest. ($1=RON3.144)